{"id":55169,"date":"2023-03-24T12:04:46","date_gmt":"2023-03-24T11:04:46","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-bioengineered-protein-drugs-market-to-reach-521-3-billion-by-2027-increasing-prevalence-of-chronic-diseases-drives-growth-researchandmarkets-com\/"},"modified":"2023-03-24T12:04:46","modified_gmt":"2023-03-24T11:04:46","slug":"global-bioengineered-protein-drugs-market-to-reach-521-3-billion-by-2027-increasing-prevalence-of-chronic-diseases-drives-growth-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-bioengineered-protein-drugs-market-to-reach-521-3-billion-by-2027-increasing-prevalence-of-chronic-diseases-drives-growth-researchandmarkets-com\/","title":{"rendered":"Global Bioengineered Protein Drugs Market to Reach $521.3 Billion by 2027: Increasing Prevalence of Chronic Diseases Drives Growth – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Global Markets for Bioengineered Protein Drugs”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe global bioengineered protein drugs market was estimated to have been worth $327.6 billion in 2021. Between 2022 and 2027, the bioengineered protein drugs market is predicted to grow at a compound annual growth rate (CAGR) of 8%, leading to a market value of $521.3 billion in 2027.\n<\/p>\n

\nAn aging population with a myriad of chronic diseases, the need for more effective and targeted therapeutics, and continuous innovation in bioengineered protein drugs are driving the bioengineered protein drugs market.\n<\/p>\n

\nBioengineered protein drugs are widely used due to their high specificity, enhanced efficacy, affinity, solubility, and low toxicity. Advances in protein synthesis have increased the complexity of bioengineered proteins being produced for therapeutic purposes.\n<\/p>\n

\nContinued development in protein drug manufacturing technologies, growing incidence of chronic diseases, the larger elderly population, improved protein-based drug efficacy, and advancements in drug delivery systems will boost the bioengineered protein drugs market. Innovations in protein drugs are accelerating quickly.\n<\/p>\n

\nFor example, in the last two years (2021 and 2022), 43 of 112, or 38.4% of all novel drug and biological product approvals, were for bioengineered protein drugs. The presence of high unmet needs and the vast potential for innovation offers tremendous growth potential for the market.\n<\/p>\n

\nThe cost of developing and producing bioengineered protein drugs is dramatically higher than for conventional (small molecule) medications and involves lengthy complex manufacturing processes and stringent regulatory requirements. The market is less susceptible to generic competition than small molecule drugs.\n<\/p>\n

\nLarge molecule or protein drugs do not have the same kind of generic competition as small molecule drugs and have a longer shelf-life in terms of patent protection. Over the past three decades, bioengineered protein drugs have revolutionized the treatment of infectious diseases, cancer, and chronic immunological diseases.\n<\/p>\n

\nPharmaceutical manufacturers are focused on developing and manufacturing novel bioengineered protein drugs for cancer, autoimmune disorders, and other life-threatening disease treatments. This is evidenced by the growing competition in the bioengineered protein drugs market.\n<\/p>\n

\nReport Scope<\/strong>\n<\/p>\n

\nThis report aims to provide a comprehensive study of the global market for bioengineered protein drugs, both in terms of quantitative and qualitative data, to help readers develop business\/growth strategies, assess the market landscape, analyze their position in the current marketplace and make informed business decisions regarding bioengineered protein drugs. Segmentation is based on the drug type, disease type, and region.\n<\/p>\n

\nIndustry growth drivers, restraints, trends, and opportunities in bioengineered protein drugs are also discussed in detail. The report also provides information on the bioengineered protein drug market competitive landscape, features detailed company profiles, and discusses the impact of COVID-19 on the market.\n<\/p>\n

\nThe report includes:<\/strong>\n<\/p>\n